ArticleBMC neurology2025
Development and validation of a nomogram for identifying cognitive impairment in patients with leukoaraiosis.
Article in BMC neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundLeukoaraiosis (LA) is a common cerebral small vessel disease in elderly populations that frequently leads to cognitive impairment and may progress to vascular dementia. Early identification of cognitive dysfunction remains challenging due to the subtle onset and lack of specific biomarkers.
objectiveTo identify key factors associated with cognitive impairment in LA patients and develop a logistic regression-based identification model to facilitate early clinical recognition and intervention.
methodsThis retrospective cross-sectional study included 390 LA patients admitted to the Department of Neurology between June 2020 and April 2023. Patients were classified into cognitive impairment (CI) and non-cognitive impairment (NCI) groups based on Montreal Cognitive Assessment (MoCA) scores. Data collected included demographics, medical history, biochemical markers, and neuroimaging features. The dataset was randomly split 7:3 into training (n = 273) and validation (n = 117) sets. Univariate analysis identified significant variables (p < 0.05), which were then incorporated into multivariate logistic regression analysis. A nomogram was constructed based on the final model, and performance was evaluated using receiver operating characteristic (ROC) curves and calibration plots for both training and validation sets.
resultsIn the training set of 273 patients, 137 had cognitive impairment and 136 did not. Univariate analysis revealed that age, Fazekas score, intracranial arterial stenosis assessment (IASA), serum creatinine, and total bilirubin were significantly associated with cognitive impairment (p < 0.05). Multivariate logistic regression identified age (OR = 1.17, 95%CI: 1.11-1.24), IASA (OR = 2.52, 95%CI: 1.64-3.68), and Fazekas score (OR = 2.58, 95%CI: 1.74-3.60) as independently associated factors. The logistic regression model demonstrated excellent discrimination with AUC values of 0.873 and 0.814 for training and validation sets, respectively. Calibration curves showed good agreement between predicted and observed probabilities, confirming model reliability.
conclusionsAge, intracranial arterial stenosis assessment, and Fazekas score are independently associated with cognitive impairment in LA patients. The logistic regression model with nomogram provides a clinically practical tool for identifying and stratifying patients with cognitive impairment, facilitating targeted clinical assessment and intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.